Sponsored by:

Tumor > Neotect

Scott Williams
Apr 2, 2002

Neotect (Tc99-m-Depreotide) (P-829)

Clinical

Chemistry and pharmacology

Patient Instructions

Imaging Protocol

Interpretation

Indications for the exam

Dosimetry

Complications/Side Effects

HAMA Formation (Immunogenicity)



Latest in Nuclear Medicine
Cerenome
Plus Therapeutics rebrands as Cerenome
August 3, 2026
Advancing molecular imaging together
Sponsored
Advancing molecular imaging together
May 24, 2026
Snmmi
SNMMI issues analysis of 2027 HOPPS proposed rule
July 29, 2026
Lumara
ITM launches new oncology therapeutics division
July 27, 2026
Related Stories
Whole Body
Nuclear Medicine
Prostascint (111In-Capromab Pendetide) (CYT-356)
Primary Ct
Nuclear Medicine
PET > PET tumor imaging > Breast Cancer
Lsegs
Nuclear Medicine
Pulmonary
Advancing molecular imaging together
Sponsor Content
Advancing molecular imaging together
More in Nuclear Medicine
Plus Therapeutics rebrands as Cerenome
By AuntMinnie.com staff writers
The move reflects the company's evolution from a therapeutics-focused organization into an integrated central nervous system (CNS) oncology company.
August 3, 2026
Cerenome
Novartis secures expanded approval for Pluvicto
By AuntMinnie.com staff writers
Pluvicto can now be used as therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, in combination with an androgen receptor pathway inhibitor.
July 31, 2026
Prostate Imaging
SNMMI issues analysis of 2027 HOPPS proposed rule
By AuntMinnie.com staff writers
The proposed rule includes several positive code-level changes for nuclear medicine providers.
July 29, 2026
Snmmi
ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
By Will Morton
Across 14 studies, PSA50 response rates (the number of patients with at least a 50% drop in PSA) ranged from 44% to 100%.
July 21, 2026
Prostate Imaging
GE HealthCare introduces MIM Anyware remote access platform
By AuntMinnie.com staff writers
The platform allows authorized users to access MIM software applications from any location without local installation.
July 21, 2026
Ge Health Care Logo New March 2023
AdvanCell raises $315M for targeted alpha therapy
By AuntMinnie.com staff writers
The company is developing ADVC001, a lead-212 (Pb-212)-based targeted alpha therapy for metastatic prostate cancer.
July 15, 2026
Cash Bills
Nucs AI, Segmed to build AI validation platform for theranostics
By AuntMinnie.com staff writers
The companies will develop disease-specific registries, curated research cohorts, and validation frameworks.
July 14, 2026
Artificial Intelligence Ai 400
Actineer completes Ra-226 recycling process to support Ac-225 supply
By AuntMinnie.com staff writers
This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.
July 14, 2026
Nuclear Medicine Worker Sm
Molecular Partners, Orano Med dose first patients in MP0712 trial
By AuntMinnie.com staff writers
MP0712 is a designed ankyrin repeat protein (DARPin) that targets delta-like ligand 3 (DLL3).
July 2, 2026
Nuclear Medicine
RefleXion Medical submits FDA 510(k) for Anchor Point tumor tracking
By AuntMinnie.com staff writers
RefleXion Medical is seeking FDA clearance for the company's Anchor Point Tracking tech for radiotherapy use.
June 30, 2026
Anchor Point Tracking, designed for use with the new RefleXion X2 platform, underpins SCINTIX therapy with higher fidelity biologic data.
Ratio Therapeutics signs Ac-225 supply agreement with PanTera
By AuntMinnie.com staff writers
Deal will support Ratio's alpha therapy programs.
June 30, 2026
Business Deal Corporate 400
Page 1 of 444
Next Page